These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs. Maruyama R; Aoki Y; Takeda S; Yokota T Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554 [TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089 [TBL] [Abstract][Full Text] [Related]
11. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. Kemaladewi DU; Hoogaars WM; van Heiningen SH; Terlouw S; de Gorter DJ; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; ten Dijke P; 't Hoen PA BMC Med Genomics; 2011 Apr; 4():36. PubMed ID: 21507246 [TBL] [Abstract][Full Text] [Related]
12. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle. Popplewell LJ; Graham IR; Malerba A; Dickson G Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027 [TBL] [Abstract][Full Text] [Related]
13. Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy. Lim KRQ; Woo S; Melo D; Huang Y; Dzierlega K; Shah MNA; Aslesh T; Roshmi RR; Echigoya Y; Maruyama R; Moulton HM; Yokota T Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35193974 [TBL] [Abstract][Full Text] [Related]
17. Systemic Intravenous Administration of Antisense Therapeutics for Combinatorial Dystrophin and Myostatin Exon Splice Modulation. Lu-Nguyen N; Dickson G; Malerba A Methods Mol Biol; 2018; 1828():343-354. PubMed ID: 30171552 [TBL] [Abstract][Full Text] [Related]
18. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy. Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245 [TBL] [Abstract][Full Text] [Related]
19. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting. Maruyama R; Yokota T Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217 [TBL] [Abstract][Full Text] [Related]
20. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression. Lee JJA; Saito T; Duddy W; Takeda S; Yokota T Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]